Autoimmune Diseases Clinical Trial
— GENIALIIOfficial title:
Biocollection for the Study of Genetic and Immunological Abnormalities in Rare Pediatric-onset Autoimmune and Auto Inflammatory Diseases
Rare diseases are defined as those that affect one person in 2,000, or around three million people in France. The majority of rare diseases are caused by genetics and tend to be severe when they begin in childhood. Autoimmune and autoinflammatory diseases, such as systemic lupus, juvenile dermatomyositis, and juvenile idiopathic arthritis, are examples of rare pediatric diseases. While autoimmune diseases are characterized by an inappropriate adaptive immune response, autoinflammatory diseases involve an excess of the innate immune response. The precise mechanisms of these diseases are not yet fully understood, but recent research has led to advances in their diagnosis and identification, particularly in early onset and familial forms. However, the rarity of these diseases and limited availability of biological samples pose significant challenges. This study aims to create a biological collection, which includes primary cells (PBMC), DNA, RNA, lymphoblastic lines, and serum, that will help identify genetic and immunological abnormalities in rare autoimmune and autoinflammatory diseases through various research projects.
Status | Not yet recruiting |
Enrollment | 400 |
Est. completion date | July 2034 |
Est. primary completion date | July 2034 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 1 Year and older |
Eligibility | Inclusion Criteria: - Patients - minor or adult patient of any age with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (<18 years), or syndromic or familial - relative of a minor or adult patient with a rare dysimmune disease characterized by autoimmunity or auto-inflammation or early lymphoproliferation, having started in childhood (<18 years of age) or syndromic or familial, - weight greater than 5 kg - Patient/parents/guardians who were informed of the study and signed the consent form. - patient affiliated to a social security scheme Healthy volunteer participants - minor or adult participants with no age restrictions - weight over 5 kg - Subject /Parents/guardians who were informed of the study and signed a consent form. - Patient affiliated to a social security scheme Exclusion Criteria: Patients - Subjects /Parents/guardians, refusing to participate in the study Healthy volunteer participants : - active infection (viral, bacterial, parasitic) - history of neoplasia (< 5 years) or current neoplasia - participants with a personal or family history of autoimmune disease - immunocompromised participant (immune deficiency or transplant recipient) - Subjects/parents/guardians refusing to participate in the study - Adults under legal protection (guardianship, curatorship) |
Country | Name | City | State |
---|---|---|---|
France | Service de rhumatologie pédiatrique Hôpital Femme-Mère-enfant | Bron | |
France | Hôpital Couple Enfant | Grenoble | |
France | Hôpital Claude Huriez (CHU de Lille) | Lille | |
France | Hôpital Jeanne de Flandre (CHU de Lille) | Lille | |
France | Hôpital Archet 2 | Nice | |
France | Hôpital Kremlin-Bicêtre (AP-HP) | Paris | |
France | Hôpital Necker-Enfants Malades (AP-HP) | Paris | |
France | Hôpital Robert Debré (AP-HP) | Paris | |
France | CLCC Henri Becquerel | Rouen | |
France | Hôpital Nord (CHU ST-Etienne) | Saint-Étienne | Saint Etienne |
Lead Sponsor | Collaborator |
---|---|
Hospices Civils de Lyon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To Identify germline and somatic mutations responsible for rare autoimmune diseases or auto-inflammatory pathologies (pediatric or syndromic or familial) that began in childhood | Identification of germline or somatic genetic mutations, based on high-throughput sequencing data (exome, genome or transcriptome). | Baseline | |
Secondary | Measurement of disease activity according to Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) | score (Min value: 0 - Max value: 105), with higher values mean higher disease activity | Baseline | |
Secondary | Levels of anti-double stranded DNA | in patients sera | Baseline | |
Secondary | Levels of complement components C3 and C4 | in patients sera | Baseline | |
Secondary | Level of IFN Signature score | Mesured by 6-gene Type 1 IFN Signature Score | Baseline | |
Secondary | Concentration of circulating IFN-alpha | In serum using single-molecule array digital ELISA technology (Simoa) | Baseline | |
Secondary | Presence or absence of anti-type I interferons autoantibodies | in patients sera | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04078698 -
Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine
|
N/A | |
Recruiting |
NCT04039763 -
RT-CGM in Young Adults at Risk of DKA
|
N/A | |
Recruiting |
NCT05670301 -
Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases
|
N/A | |
Completed |
NCT03266172 -
A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses
|
Phase 1 | |
Completed |
NCT03649412 -
A Study to Investigate the Pharmacokinetics (PK) of Modified Release (MR) Prototype Coated Tablet Formulations of GSK2982772
|
Phase 1 | |
Recruiting |
NCT04561557 -
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
|
Early Phase 1 | |
Completed |
NCT03173144 -
Chronic Inflammatory Disease, Lifestyle and Treatment Response
|
||
Completed |
NCT00975936 -
Phase 0 Microdose Study
|
Phase 1 | |
Not yet recruiting |
NCT05969821 -
Clonal Hematopoiesis of Immunological Significance
|
||
Completed |
NCT01210716 -
Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device
|
Phase 3 | |
Completed |
NCT00820469 -
Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab
|
Phase 4 | |
Completed |
NCT01953523 -
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
|
N/A | |
Withdrawn |
NCT03239600 -
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)
|
Phase 2 | |
Completed |
NCT04872257 -
Oral Vitamin D Supplementation Combined With Phototherapy as a Treatment for Vitiligo
|
N/A | |
Recruiting |
NCT06019611 -
Epidural Stimulation in Multiple Sclerosis
|
N/A | |
Recruiting |
NCT05030779 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus
|
Early Phase 1 | |
Not yet recruiting |
NCT03899298 -
Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
|
Phase 1 | |
Completed |
NCT04005456 -
Personalized Lifestyle Intervention for Improving Functional Health Outcomes Using N-of-1 Tent-Umbrella-Bucket Design
|
N/A | |
Recruiting |
NCT05085444 -
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma
|
Early Phase 1 | |
Recruiting |
NCT05853835 -
First-in-Human Trial in Healthy Adult Volunteers to Evaluate Safety, Tolerability and PK of LAPIX Study Drug; LPX-TI641
|
Phase 1 |